TFF Pharmaceuticals (NASDAQ:TFFP) reported quarterly losses of $(2.01) per share which beat the analyst consensus estimate of $(2.12) by 5.19 percent. This is a 19.6 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $114.33 thousand which beat the analyst consensus estimate of $100.00 thousand by 14.33 percent. This is a 63.45 percent decrease over sales of $312.78 thousand the same period last year.
TFF Pharmaceuticals Q4 EPS $(2.01) Beats $(2.12) Estimate, Sales $114.33K Beat $100.00K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.